copanlisib: Clinical Trials

3 trials of copanlisib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 1 terminated. 3 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 33Completed 2, Terminated 1

Follow copanlisib: new trials by email Literature Review of copanlisib trials Research Report on copanlisib

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)
Copanlisib (BAY80-6946), Placebo, Rituximab - Lymphoma, Non-Hodgkin
Phase 3TerminatedBayer5512016-01-062024-12-11
Phase III Copanlisib in Rituximab-refractory iNHL
Copanlisib (BAY 80-6946) - Lymphoma, Non-Hodgkin
Phase 3CompletedBayer252015-09-222023-11-18
Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)
Copanlisib (Aliqopa, BAY80-6946), Placebo, Rituximab - Lymphoma,Non-Hodgkin
Phase 3CompletedBayer4582015-08-032025-10-14

Conditions studied

Lymphoma, Non-Hodgkin (3)

Sponsors

Bayer (3)

Countries

Brazil (3)  ·  Bulgaria (3)  ·  Greece (3)  ·  Italy (3)  ·  Poland (3)  ·  Russia (3)  ·  South Africa (3)  ·  South Korea (3)  ·  Taiwan (3)  ·  Turkey (Türkiye) (3)  ·  Australia (2)  ·  Belgium (2)  ·  Chile (2)  ·  China (2)  ·  France (2)

Results publications

PMID 33848462, PMID 34389273, PMID 38226495, PMID 39058951

NIH funding

2014 (1), 2015 (1)